Aquaculture genetics, health and nutrition firm Benchmark's much-touted new sea lice treatment is facing a speedbump in its drive to launch commercially in Norway, following a vote in the European Parliament on June 9.

The European Parliament passed a resolution put forward by Irish Green Party Parliamentarian Grace O’Sullivan that could potentially hinder progress toward authorization for use of the treatment in Norway.

O’Sullivan’s resolution aims to amend regulation ratified by the European Commission in April that effectively approved the use of Benchmark’s novel sea lice treatment BMK08 by agreeing maximum residue limits for its active ingredient, imidacloprid, on finfish.